basal cell carcinoma

Skin cancer advancesGenetic profiling is valuable in both diagnosis and prognosis of skin cancer. Hedgehog inhibitors and (superficial radiation therapy) SRT are strong contenders for treating nonmelanoma skin cancer. Advances in targeted therapies and biologics are part of the new wave of melanoma treatments.
Psoriasis and skin cancerCyclosporine and PUVA clearly increase the risk of squamous cell carcinomas, and there is evidence that TNF blockers and methotrexate may do so to a lesser degree. UVB phototherapy has not been shown to cause skin cancer. Acitretin offers protection against the development of basal cell and squamous cell carcinomas.
Update on advanced basal cell carcinoma diagnosis and treatmentDespite increased insight on skin cancer risk factors, the incidence continues to rise worldwide. This review article summarizes new treatment options available, which help to redefine and expand the diagnosis of advanced BCC and allow dermatologists to offer more effective therapy to a broader population.
Staying current with therapeutic advances and expert insightsThis month we offer new insights and data to aid diagnosis and treatment of difficult conditions, as well as practical approaches to optimize outcomes.
Vismodegib study confirms safety, efficacy for BCCThe largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.
Improving accuracy in NMSC diagnosisThe trend toward smaller biopsies may compromise the accuracy of dermatopathologists' diagnoses.
GlobalMed Technologies acquires Omnilux MedicalGlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.
Cutting edge techniques provide options for skin cancerNew technologies for managing skin cancer were a topic of discussion at a scientific session at the American Society for Dermatologic Surgery’s 2015 annual meeting in Chicago in October. Seaver L. Soon, M.D., division of dermatology and dermatologic surgery at Scripps Clinic, La Jolla, Calif., was one of the moderators for the scientific discussion titled, “The Cutting Edge: New Technologies for Managing Skin Cancer.” Learn more
High-risk skin cancer needs multidisciplinary management
High-risk skin cancer needs multidisciplinary managementImmunosuppressed patients have a greater risk for developing high-risk non-melanoma skin cancer, which can typically be more aggressive in this patient population. As such, a multidisciplinary approach is required when contemplating appropriate treatment and management of this patient population.
Sonidegib offers new option for basal cell cancerA newly approved medication called sonidegib (Odomzo) gives physicians a second option in a class of medications designed to treat a small number of patients who suffer from locally advanced basal cell carcinoma and meet other criteria. Learn more